Table 12.

Tabular summary

Infliximab
First approved in Germany	2004 (Psoriasis arthritis)/2005 (psoriasis vulgaris)
Recommended control parameters	Prior to therapy exclusion of tuberculosis, during therapy: leukocyte and platelet counts, liver value controls, signs of clinical infection
Recommended initial dosage	5 mg/kg BW at week 0, 2, 6
Recommended maintenance dosage	5 mg/kg BW in dosage intervals of 8 weeks
Expected beginning of clinical effect	After 1–2 weeks
Response rate	PASI 75 in ≥80% of the patients with moderate to severe psoriasis vulgaris (LE 1)
Important contraindications (limited selection)	Acute or chronic infections, tuberculosis, cardiac failure NYHA III–IV, pregnancy and nursing
Important ADRs (limited selection)	Infusion reactions, severe infections, progression of heart failure NYHA III–IV, very rare liver failure, autoimmune phenomena
Important drug interactions (limited selection)	Anakinra (IL-1 receptor antagonist)
Other	–